ArticleReviews in cardiovascular medicine2025
Moderating Role of Anemia on the Association between Blood Urea Nitrogen and Atherosclerotic Cardiovascular Disease in Hypertension.
Article in Reviews in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anemia or blood urea nitrogen (BUN) are both associated with atherosclerotic cardiovascular disease (ASCVD) in hypertension (HTN). However, the relationship between anemia, BUN, and ASCVD remains unclear in HTN. This study aimed to investigate the relationship between BUN, anemia, and ASCVD in HTN patients, and further investigated the moderating effect of anemia on the relationship between BUN and ASCVD. Methods: In total, 15,109 HTN patients were included based on the National Health and Nutritional Examination Survey (NHANES) from 1999 to 2018. The weighted univariate logistic regression model was utilized to select potential covariates. The relationship between BUN, anemia, and ASCVD was investigated using weighted univariate and multivariate logistic regression models. All results were expressed as odds ratios (ORs) and 95% confidence intervals (CIs). Results: A total of 15,109 HTN patients were included for final analysis. BUN level ≥4.69 mmol/L was related to higher odds of ASCVD in HTN patients (OR = 1.68, 95% CI: 1.51-1.88). Similarly, anemia was also associated with increased odds of ASCVD in HTN patients (OR = 1.45, 95% CI: 1.22-1.73). In patients with anemia, a BUN level ≥4.69 mmol/L was associated with increased odds of ASCVD when compared to patients who had a BUN level <4.69 mmol/L (OR = 2.95, 95% CI: 2.05-4.25). Anemia affected the association between BUN and ASCVD in HTN patients. Conclusions: Anemia moderates the association between BUN and ASCVD in HTN patients, amplifying the adverse effects. The findings show the importance of comprehensive management strategies that included renal function monitoring and anemia treatment in HTN patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.